August 5 th, Calendar Year Second Quarter Conference Call
|
|
- Noah Phillips
- 5 years ago
- Views:
Transcription
1 August 5 th, 2015 Calendar Year Second Quarter Conference Call 0
2 Forward - Looking Statements Note: Certain statements in this presentation are forward-looking statements." These statements relate to future events or the Company s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the Company s expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this presentation, including certain statements contained in Management s Discussion and Analysis of Financial Condition and Results of Operations in the Company s quarterly reports on Form 10-K and Form 10-Q are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, potential or the negative of those terms or other comparable terminology. Please see the Company's documents filed with the Securities and Exchange Commission, including the Company's annual reports filed on Form 10-K, quarterly reports on Form 10-Q, and any amendments thereto for a discussion of certain important risk factors that relate to forward-looking statements contained in this presentation. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, including but not limited to, the successful integration of the Omega Pharma Invest NV business and future actions that may be taken by Mylan N.V. in furtherance of its unsolicited proposal to acquire control of the Company. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forwardlooking statements. Any forward-looking statements are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 1
3 Irish Takeover Rules and Non-GAAP Measures The directors of Perrigo accept responsibility for the information contained in this presentation. To the best of the knowledge and belief of the directors of Perrigo (who have taken all reasonable care to ensure such is the case), the information contained in this presentation is in accordance with the facts and does not omit anything likely to affect the import of such information. A person interested in 1% or more of any class of relevant securities of Perrigo may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules. A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed and can be found on the Irish Takeover Panel's website at "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel's website. If you are in any doubt as to whether you are required to disclose a "dealing" under Rule 8, please consult the Irish Takeover Panel's website at or contact the Irish Takeover Panel on telephone number ; fax number The EPS guidance for calendar year 2015 provided by Perrigo in this presentation constitutes a profit forecast for the purposes of the Irish Takeover Rules. This profit forecast will be reported on by Perrigo's reporting accountants and financial advisors in accordance with Rule 28.3 of the Irish Takeover Rules at the relevant time. Other than the reference to the aforementioned guidance provided by Perrigo for calendar year 2015, nothing in this presentation is intended to be a profit forecast or asset valuation and no statement in this presentation, other than the aforementioned profit forecast, should be interpreted to mean that the earnings per Perrigo share for the current or future financial periods will necessarily be greater than those for the relevant preceding financial period. This Presentation contains non-gaap measures. The reconciliation of those measures to the most comparable GAAP measures is included at the end of this presentation. A copy of this presentation, including the reconciliations, is available on our website at Non-GAAP guidance for calendar 2015 excludes among other items listed on Table I, restructuring, unusual litigation charges, along with costs associated with an unsolicited offer to acquire the Perrigo Company plc by Mylan N.V. ("Mylan"). At this time, a reconciliation to GAAP for these measures for calendar 2015 is impracticable to provide given the uncertainty and potential variability of these items. The unavailable reconciling items could significantly impact the Company's financial results. Additional Information and Where to Find It The exchange offer for the outstanding shares of Perrigo described herein has not yet commenced. If and when an exchange offer by Mylan is commenced, Perrigo intends to file a solicitation/recommendation statement with respect to such exchange offer with the Securities and Exchange Commission ( SEC ). Security holders are urged to read the solicitation/recommendation statement and other relevant materials if and when they become available because they will contain important information. The solicitation/recommendation statement and other SEC filings made by Perrigo may be obtained (when available) without charge at the SEC s website at and at the investor relations section of the Perrigo website at perrigo.investorroom.com. 2
4 Consolidated Q2CY15 GAAP Financials ($ in millions, except per share amounts) Q2CY15 Q2CY14 % Change Y/Y* Net Sales $1,532 $1, % Cost of Sales % Gross Profit $628 $ % Distribution % R&D % SG&A % Operating Income $227 $ % Net Income $56 $132 (57 %) Diluted Income Per Share $0.38 $0.98 (61 %) *Adjusted Margin changes as a % to sales may not calculate due to rounding 3
5 Perrigo Consolidated Q2CY15 As Adjusted* ($ in millions, except per share amounts) Q2CY15 Q2CY14 % Change Y/Y** Net Sales $1,532 $1, % Adjusted Cost of Sales % Adjusted Gross Profit $753 $ % Distribution % Adjusted R&D % Adjusted SG&A % Adjusted Operating Income $437 $ % Adjusted Net Income $320 $ % Adjusted Diluted EPS $2.18 $ % Adj. Gr. Margin Q2CY15-Q2CY13 Adj. Op. Margin Q2CY15-Q2CY13 *See attached financial schedule for reconciliation to GAAP numbers **Adjusted Margin changes as a % to sales may not calculate due to rounding 4
6 Net Sales and Operating Income Q2CY15 As Adjusted* ($ in millions) Q2CY15 Q2CY14 % Change Y/Y** % Change Constant Currency Y/Y*** Consolidated Perrigo Net Sales $1,532 $1, % 36 % Adjusted Operating Income % Consumer Healthcare Net Sales (3 %) (2 %) Adjusted Operating Income % Branded Consumer Healthcare Net Sales 401 Adjusted Operating Income 77 Rx Pharmaceuticals Net Sales % 11 % Adjusted Operating Income % Specialty Sciences Net Sales (3 %) 5 % Adjusted Operating Income % *See attached financial schedule for reconciliation to GAAP numbers **Changes may not calculate due to rounding ***Excludes impact of currency translation compared to prior year, including Fx impact on Tysabri royalty stream 5
7 $1 Billion* in Total New Products Over the Next Three Years Consumer Healthcare (Legacy CHC + NUT) ANDA Pipeline >$3.6B in National Brand Sales *Perrigo Long Term Plan 6
8 US All Category Trailing 52 Weeks Store Brand National Brand Category Total OTC Diabetes -6.4% -2.8% 3.4% 1.5% 8.3% 6.6% Gastrointestinal 2.4% 7.9% Smoking Cessation -11.2% 2.9% 5.8% 12.5% Vitamins (*VMS) Infant Formula Cough, Cold, Allergy, Sinus Analgesics -1.9% -1.1% 5.6% 3.4% 2.7% 2.5% 4.0% 9.7% 0.7% 8.6% 5.4% 12.2% SB impacted by expected return of large NB competitor -20% -15% -10% -5% 0% 5% 10% 15% 20% *Vitamins, Minerals, and Supplements Source: IRI MULO through June 28,
9 Consumer Healthcare Segment Q2CY15 As Adjusted* ($ in millions) Q2CY15 Q2CY14 % Change Y/Y** Segment Highlights Net Sales $746 $772 (3 %) Adjusted Gross Profit $269 $253 6 % Adjusted Gross Margin 36.0 % 32.7% 330 bps Adjusted Operating Expenses (7 %) Adjusted Operating Income $160 $ % Adjusted Operating Margin 21.4 % 17.5% 390 bps Adj. Gr. Margin Q2CY15-Q2CY14 Adj. Op. Margin Q2CY15-Q2CY14 Net Sales FX impact of ($12) million or (1%) Adjusted Operating Income increased $24 million primarily due to adjusted gross profit flow through and lower selling expenses New product sales of $77 million *See attached financial schedule for reconciliation to GAAP numbers **Adjusted margin changes as a % to sales may not calculate due to rounding 8
10 Branded Consumer Healthcare Segment Q2CY15 As Adjusted* ($ in millions) Q2CY15 Segment Highlights Net Sales $401 Adjusted Gross Profit $213 Adjusted Gross Margin 53.0 % Adjusted Operating Expenses 136 Adjusted Operating Income $77 Adjusted Operating Margin 19.2 % Top 20 brands grew 11% on a constant currency basis compared to last year New product sales of $33 million Adj. Gr. Margin Q2CY15-Q2CY14 Adj. Op. Margin Q2CY15-Q2CY14 *See attached financial schedule for reconciliation to GAAP numbers 9
11 Rx Pharmaceuticals Segment Q2CY15 As Adjusted* ($ in millions) Q2CY15 Q2CY14 % Change Y/Y** Segment Highlights Net Sales $278 $ % Adjusted Gross Profit $180 $ % Adjusted Gross Margin 64.8% 60.4 % 440 bps Adjusted Operating Expenses % Adjusted Operating Income $138 $ % Adjusted Operating Margin 49.5% 48.3 % 120 bps Adj. Gr. Margin Q2CY15-Q2CY14 Adj. Op. Margin Q2CY15-Q2CY14 Net Sales FX impact of ($2) million or (1%) Adjusted Gross Margin increase driven by product mix and pricing initiatives Adjusted Operating Income improved 13% and included increased R&D and specialty pharmaceuticals sales force investments *See attached financial schedule for reconciliation to GAAP numbers **Adjusted margin changes as a % to sales may not calculate due to rounding 10
12 Specialty Sciences Segment Q2CY15 As Adjusted* ($ in millions) Q2CY15 Q2CY14 % Change Y/Y** Segment Highlights Net Sales $84 $86 (3 %) Adjusted Gross Profit $84 $86 (3 %) Adjusted Gross Margin 100.0% % 0 bps Adjusted Operating Expenses 4 7 (41)% Adjusted Operating Income $79 $79 1 % Adjusted Operating Margin 94.8% 91.4 % 340 bps Global Tysabri Performance (in millions)*** Net Sales FX impact of ($7) million or (8%) CYQ214 included $10 million of net sales recognized from agreement with Italian Medicines Agency (AIFA) $463 $534 $195 $284 $269 $250 Q2CY15 US ROW Q2CY14 *See attached financial schedule for reconciliation to GAAP numbers **Adjusted margin changes as a % to sales may not calculate due to rounding *** Data according to Biogen Inc. 11
13 CALENDAR YEAR 2015 Segment Guidance Calendar Year 2015 % of Total Net Sales Consumer Healthcare Legacy Consumer Healthcare and Nutritionals (Infant nutrition and VMS) businesses; Legacy Israel Pharmaceuticals and Diagnostics business Branded Consumer Healthcare * Omega business Rx Pharmaceuticals Identical to legacy Rx Pharmaceuticals segment ~50% ~20% (9 months) ~20% Consumer facing businesses comprise ~75% of total net sales on an annual basis *Includes only 9 months for Omega acquisition translated at 1:$
14 CALENDAR YEAR 2015 Consolidated Guidance Net Sales Calendar Year /13/2015 Guidance** Calendar Year* 2014 (Recast) $5.4B - $5.7B (9 months of Omega) $4.17B Adjusted DSG&A as % of Net Sales *** ~17.5% 12.9% Adjusted R&D as % of Net Sales *** ~3.5% 3.9% Adjusted Operating Margin ~27% 27.1% Capital Expenditures $125M - $155M $142M Interest Expense ~$170M $110M Adjusted Effective Tax Rate ~17% 17.3% Adjusted EPS $ $8.00/share $6.27/share Adjusted Diluted Shares Outstanding 144M 135M *See Appendix for reconciliation of CY 2014 Non-GAAP measures to GAAP **Includes only 9 months for Omega acquisition translated at 1:$1.09 ***Percentages are +/- 75 basis points 13
15 Confident in Perrigo s Stand-Alone Strategy Mylan N.V. offer substantially undervalues Perrigo Superior value delivered to shareholders by executing on Perrigo s Base Plus Plus Plus strategy Strong history of Perrigo s responsible corporate governance Mylan N.V. combination poses risks to shareholders Difficult path to completion 14
16 Questions? Arthur J. Shannon Vice President, Investor Relations and Global Communications (269) Bradley Joseph Director, Investor Relations and Global Communications (269)
17 APPENDIX Table I PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES (in millions, except per share amounts) (unaudited) Three Months Ended Consolidated June 27, 2015 June 28, 2014 % Change GAAP Non-GAAP Adjustments As Adjusted GAAP (2) Non-GAAP Adjustments (2) As Adjusted (2) GAAP As Adjusted Net sales $ 1,531.6 $ $ 1,531.6 $ 1,144.2 $ $ 1, % 34% Cost of sales (a,b) (a) % 23% Gross profit % 48% Operating expenses Distribution % 68% Research and development (c) % 17% Selling (a) (a) % 168% Administration (a,d) (a,g) % 34% Restructuring (0.1) (0.1) (h) -101% NM Total operating expenses % 71% Operating income % 35% Interest expense, net % 75% Other expense, net (e) (i) 2.1 NM 143% Loss on extinguishment of debt NM NM Income before income taxes % 30% Income tax expense (35.4) (f) (j) % 6% Net income $ 56.4 $ $ $ $ $ % 37% Diluted earnings per share $ 0.38 $ 2.18 $ 0.98 $ % 25% Diluted weighted average shares outstanding % 9% Effective tax rate 64.2% 17.0% 20.4% 21.0% Gross margin (1) 41.0% 49.1% 36.3% 44.5% Operating margin (1) 14.8% 28.5% 17.3% 28.4%
18 APPENDIX Table I (continued) PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES (in millions, except per share amounts) (unaudited) Tickmark Description Second Calendar Quarter Tickmark Legend (1) Ratios calculated using exact numbers (2) Amounts may not sum or cross-foot due to rounding NM Calculations not meaningful (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) Acquisition-related amortization expense Inventory step-up related to the Omega acquisition ($15.6 million) Initial payment made in connection with an R&D arrangement Primarily legal and consulting fees related to the Mylan N.V. defense ($13.4 million) and acquisition-related expenses ($18.6 million) Goodwill impairment charge ($6.8 million), losses on derivatives ($5.5 million), equity method investment losses ($3.5 million), and investment impairment of ($1.7 million) Tax effect of non-gaap adjustments described above along with the impact of acquisitions on deferred tax balances Loss contingency accrual on unusual litigation ($15.0 million) Restructuring and integration-related charges related primarily to the Elan acquisition Equity method investment losses Tax effect of non-gaap adjustments
19 APPENDIX Table II PERRIGO COMPANY PLC REPORTABLE SEGMENTS RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited) Three Months Ended Consumer Healthcare June 27, 2015 June 28, 2014 % Change GAAP Non-GAAP Adjustments As Adjusted GAAP Non-GAAP Adjustments As Adjusted GAAP As Adjusted Net sales $ $ $ $ $ $ % -3% Cost of sales (a) (a) % -8% Gross profit % 6% Operating expenses (a,b) (a,b) % -7% Operating income $ $ 16.3 $ $ $ 17.2 $ % 18% Gross margin (1) 34.6% 36.0% 31.8% 32.7% Operating margin (1) 19.2% 21.4% 15.3% 17.5% (1) Ratios calculated using exact numbers (a) Acquisition-related amortization expense (b) Restructuring charges and other integration-related expenses
20 APPENDIX Table II (continued) PERRIGO COMPANY PLC REPORTABLE SEGMENTS RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited) Three Months Ended Branded Consumer Healthcare June 27, 2015 (2) GAAP Non-GAAP Adjustments As Adjusted Net sales $ $ $ Cost of sales (a,b) Gross profit Operating expenses (a,c) Operating income $ 26.6 $ 50.4 $ 77.0 Gross margin (1) 47.4% 53.0% Operating margin (1) 6.6% 19.2% (1) Ratios calculated using exact numbers (2) Only includes activity from March 30, 2015 to June 27, 2015 (a) Acquisition-related amortization expense (b) Inventory step-up of $15.6 million (c) Integration-related expenses
21 APPENDIX Table II (Continued) PERRIGO COMPANY PLC REPORTABLE SEGMENTS RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited) Three Months Ended Rx Pharmaceuticals June 27, 2015 June 28, 2014 % Change GAAP Non-GAAP Adjustments As Adjusted GAAP Non-GAAP Adjustments As Adjusted GAAP As Adjusted Net sales $ $ $ $ $ $ % 10% Cost of sales (a) (a) % -2% Gross profit % 18% Operating expenses (a,b,c,d) (a,e) % 38% Operating income $ 99.5 $ 38.2 $ $ 89.3 $ 33.0 $ % 13% Gross margin (1) 58.0% 64.8% 53.5% 60.4% Operating margin (1) 35.7% 49.5% 35.2% 48.3% (1) Ratios calculated using exact numbers (a) Acquisition-related amortization expense (b) Initial payment of $18.0 million made in connection with an R&D arrangement (c) Restructuring and other integration related expenses (d) Write-off of contingent consideration of $1.0 million (e) Loss contingency accrual of $15.0 million
22 APPENDIX Table II (Continued) PERRIGO COMPANY PLC REPORTABLE SEGMENTS RECONCILIATION OF NON-GAAP MEASURES (in millions) (unaudited) Three Months Ended Specialty Sciences June 27, 2015 June 28, 2014 % Change GAAP Non-GAAP Adjustments As Adjusted GAAP Non-GAAP Adjustments As Adjusted GAAP As Adjusted Net sales $ 83.6 $ $ 83.6 $ 85.9 $ $ % -3% Cost of sales (a) (a) 7% NM Gross profit % -3% Operating expenses (a) (b) % -41% Operating income $ 6.4 $ 72.8 $ 79.2 $ 4.9 $ 73.6 $ % 1% Gross margin (1) 13.3% 100.0% 21.1% 100.0% Operating margin (1) 7.7% 94.8% 5.8% 91.4% (1) Ratios calculated using exact numbers NM - Calculations are not meaningful (a) Acquisition-related amortization expense (b) Elan restructuring and other integration-related expenses
23 APPENDIX Table III PERRIGO COMPANY PLC REPORTABLE SEGMENTS (in millions) (unaudited) Consolidated Q2 CY13 Net sales $ Reported gross profit $ Acquisition-related amortization (1) 22.7 Inventory Step-up 1.2 Adjusted gross profit $ Adjusted gross margin 39.3% Reported operating income $ Acquisition-related amortization (1) 29.0 Inventory Step-up 1.2 Write-off of IPRD 9.0 Restructuring 2.9 Acquisition costs 3.0 Adjusted operating income $ Adjusted operating margin 23.3% (1) Amortization of acquired intangible assets related to business combinations and asset acquisitions.
24 APPENDIX Table IV PERRIGO COMPANY PLC (in millions) (unaudited) Three Months Ended June 27, 2015 June 28, 2014 Reported Adjusted Reported Adjusted Net sales 1, , , ,144.2 Less: Q2 CY15 acquisitions (411.7) (411.7) Organic net sales 1, , , ,144.2 Three Months Ended % Change June 27, 2015 June 28, 2014 Reported Adjusted Gross profit % 47.9% 320 bps Less: Q2 CY15 acquisitions (194.1) (218.8) Organic gross profit % 4.9% Three Months Ended June 27, 2015 June 28, 2014 % Change Reported Adjusted Reported Adjusted Reported Adjusted Operating income % 35% Less: Q2 CY15 acquisitions (24.3) (76.8) Organic operating income % 11%
25 APPENDIX Table V PERRIGO COMPANY PLC (in millions) (unaudited) Consumer Healthcare and Branded Consumer Healthcare GAAP Three Months Ended June 27, 2015 (2) Non-GAAP Adjustments As Adjusted Net sales $ 1,147.6 $ $ 1,147.6 Cost of sales (a,b) Gross profit Operating expenses (a,c) Operating income $ $ 66.7 $ Gross margin (1) 39.1% 41.9% Operating margin (1) 14.8% 20.6% (1) Ratios calculated using exact numbers (2) The Branded Consumer Healthcare segment includes activity from March 30, 2015 to June 27, 2015 (a) Acquisition-related amortization expense (b) Inventory step-up of $15.6 million (c) Restructuring charges and other integration-related expenses
26 APPENDIX Table VI PERRIGO COMPANY PLC (in millions) (unaudited) Q2 CY15 Q2 CY15 % Change Consolidated net sales $ 1,531.6 $ 1,144.2 Less: Branded Consumer Healthcare net sales Less: FX impact on consolidated net sales (23.0) Consolidated net sales less Branded Consumer Healthcare and FX $ 1,153.4 $ 1, %
Second Quarter Calendar Year 2018 Financial Results August 9, 2018
Second Quarter Calendar Year 2018 Financial Results August 9, 2018 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future
More informationFourth Quarter & Calendar Year 2016 Earnings Conference Call May 23, 2017
Fourth Quarter & Calendar Year 2016 Earnings Conference Call May 23, 2017 Forward Looking Statements Certain statements in this presentation are forward-looking statements. These statements relate to future
More informationPerrigo Fiscal Fourth Quarter Conference Call August 18, 2009
Perrigo Fiscal Fourth Quarter Conference Call August 18, 2009 Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the
More informationAnnual General Meeting July 20, 2017
Annual General Meeting July 20, 2017 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future
More information2018 J.P. Morgan Healthcare Conference January 9, 2018
2018 J.P. Morgan Healthcare Conference January 9, 2018 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the
More informationPerrigo: Creating Superior Value for Shareholders. April 2015
Perrigo: Creating Superior Value for Shareholders April 2015 Forward Looking Statements The directors of Perrigo accept responsibility for the information contained in this presentation. To the best of
More informationCVS Health Corporation Supplemental Financial Information Preliminary and Unaudited. Fourth Quarter 2014 Earnings Release February 10, 2015
CVS Health Corporation Supplemental Financial Information Preliminary and Unaudited Earnings Release February 10, 2015 The information in this report includes non-gaap financial measures related to our
More informationCREDIT SUISSE Phoenix, AZ
CREDIT SUISSE Phoenix, AZ November 9-10, 2011 Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the Securities Exchange
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference San Francisco, CA January 10, 2011 Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference January 13 th, 2014 Consumer Healthcare Nutritionals Rx Pharmaceuticals Specialty Sciences Active Pharmaceutical Ingredients Forward Looking Statements Certain statements
More informationMylan: Q EARNINGS August 8, Q Earnings All Results are Unaudited
Mylan: Q2 2018 EARNINGS August 8, 2018 Q2 2018 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationMylan Q EARNINGS November 5, Q Earnings All Results are Unaudited
Mylan Q3 EARNINGS November 5, Q3 Earnings All Results are Unaudited Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to the safe harbor
More informationQuality, Affordable Healthcare Products Since J.P. Morgan Healthcare Conference. January 7th, 2013
Quality, Affordable Healthcare Products Since 1887 J.P. Morgan Healthcare Conference January 7th, 2013 Forward Looking Statements Certain statements in this presentation are forward-looking statements
More informationQ3 FY16 FINANCIAL RESULTS CONFERENCE CALL May 10, 2016 at 5:00 pm ET
Q3 FY16 FINANCIAL RESULTS CONFERENCE CALL May 10, 2016 at 5:00 pm ET SAFE HARBOR This presentation may contain certain comments, which are forward-looking statements that involve plans, strategies, economic
More informationCFO COMMENTARY Q4 FY 2018
Q4 FY 2018 FINANCIAL INFORMATION AND CONFERENCE CALL Please see the accompanying earnings press release available at www.scansource.com in the Investor Relations section. The information included in this
More informationQ3 Fiscal Year 2019 Financial Highlights
Q3 Fiscal Year 2019 Financial Highlights For the quarter ended October 31, 2018 November 29, 2018 Forward Looking Statements Certain statements in this communication may contain forward looking statements
More informationCFO COMMENTARY Q1 FY 2019
Q1 FY 2019 FINANCIAL INFORMATION AND CONFERENCE CALL Please see the accompanying earnings press release available at www.scansource.com in the Investor Relations section. The information included in this
More informationMcKesson Corporation Q2 Fiscal 2019 Financial Performance. Financial Results and Company Highlights October 25, 2018
McKesson Corporation Q2 Fiscal 2019 Financial Performance Financial Results and Company Highlights October 25, 2018 Forward-Looking Statements Some of the information in this presentation is not historical
More informationMylan Q Non-GAAP Reconciliations November 5, Q Earnings All Results are Unaudited
Mylan Q3 Non-GAAP Reconciliations November 5, Q3 Earnings All Results are Unaudited Non-GAAP Financial Measures This presentation includes the presentation and discussion of certain financial information
More informationCFO COMMENTARY Q3 FY 2018
Q3 FY 2018 FINANCIAL INFORMATION AND CONFERENCE CALL Please see the accompanying earnings press release available at www.scansource.com in the Investor Relations section. The information included in this
More informationThird Quarter 2018 Teleconference Supplemental Data
Third Quarter 2018 Teleconference Supplemental Data Cautionary Statement Forward-Looking Information This communication contains forward looking statements as that term is defined in the Private Securities
More informationNet sales $267.3 $258.2 $524.0 $507.3 Cost of goods sold Gross profit
Unaudited Consolidated Statements of Operations Three Months Ended Six Months Ended June 30, June 30, (in millions, except per share data) 2006 2005 2006 2005 Net sales $267.3 $258.2 $524.0 $507.3 Cost
More informationTwelve Months Ended December 31 (In thousands, except per share amounts)
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended (In thousands, except per share amounts) 2012 2011 2012 2011 from continuing operations: Service revenues $ 571,581 $ 640,736 $ 2,340,996
More informationQ3 FY 2015 FINANCIAL RESULTS CONFERENCE CALL April 30, 2015 at 5:00 pm ET
Q3 FY 2015 FINANCIAL RESULTS CONFERENCE CALL April 30, 2015 at 5:00 pm ET SAFE HARBOR This presentation may contain certain comments, which are forward-looking statements that involve plans, strategies,
More informationNon-GAAP Reconciliation as of April 26, 2018
Non-GAAP Reconciliation as of April 26, 2018 Non-GAAP Reconciliations: As part of its Q1 2018 earnings announcement on April 26, 2018, Baxter presented historical results for Q1 2017. Baxter also presented
More informationFiscal 2017 First Quarter Results. 5 January 2017
Fiscal 2017 First Quarter Results 5 January 2017 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not
More informationQ1 Fiscal Year 2019 Financial Highlights
Fiscal Year 2019 Financial Highlights For the quarter ended April 30, 2018 May 31, 2018 Forward-Looking Statements Certain statements in this communication may contain forward-looking statements within
More information2Q 2017 Earnings Presentation. August 8, 2017
2Q 2017 Earnings Presentation August 8, 2017 Caution Concerning Forward-Looking Statements and Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the
More informationECOLAB SECOND QUARTER 2018
2Q 2018 Overview Sales: ECOLAB SECOND QUARTER 2018 Reported sales +7%; fixed currency sales were +4%, with acquisition adjusted fixed currency sales +5%. New business growth, share gains, pricing and new
More informationFAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) June 30, September 30, 2016 2015 ASSETS: Current assets: Cash and cash equivalents $ 118,155 $ 86,120 Accounts receivable, net 155,196 158,773 Prepaid
More informationECOLAB THIRD QUARTER 2018
3Q 2018 Overview Sales: ECOLAB THIRD QUARTER 2018 Reported sales +5%; fixed currency sales were +6%, with acquisition adjusted fixed currency sales +7%. New business growth, share gains, pricing and new
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) March 31, September 30, 2016 2015 ASSETS: Current assets: Cash and cash equivalents $ 85,374 $ 86,120 Accounts receivable, net 155,207 158,773 Prepaid
More informationSecond Quarter 2018 Financial Review and Analysis (preliminary, unaudited)
Second Quarter 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same period in the prior year. 1 Second
More informationSyneos Health. Q4 and Full Year 2017 Financial Results. February 28, 2018
Syneos Health Q4 and Full Year 2017 Financial Results February 28, 2018 Forward-Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the
More informationFiscal 2018 Third Quarter Results. 28 June 2018
Fiscal 2018 Third Quarter Results 28 June 2018 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not
More informationFourth Quarter and Fiscal 2016 Results. 20 October 2016
Fourth Quarter and Fiscal 2016 Results 20 October 2016 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that
More informationECOLAB FIRST QUARTER 2018
1Q 2018 Overview Sales: ECOLAB FIRST QUARTER 2018 Reported sales +10% and fixed currency and acquisition adjusted fixed currency sales +6%. New business growth, share gains, pricing and new product introductions
More informationCORNING INCORPORATED AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF INCOME (Unaudited; in millions, except per share amounts)
CONSOLIDATED STATEMENTS OF INCOME (Unaudited; in millions, except per share amounts) 2012 2011 Net sales $ 1,920 $ 1,923 Cost of sales 1,106 1,049 Gross margin 814 874 Operating expenses: Selling, general
More informationFirst Quarter 2018 Financial Review and Analysis (preliminary, unaudited)
First Quarter 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same period in the prior year. 1 First Quarter
More informationFiscal 2019 First Quarter Results. December 20, 2018
Fiscal 2019 First Quarter Results December 20, 2018 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are
More informationEndo International plc
Endo International plc UBS Global Healthcare Conference May 21, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of
More informationQ Financial Results
Q1 2018 Financial Results May 3, 2018 Copyright Fortinet Inc. All rights reserved. Safe Harbor Statement Information, statements and projections contained in these presentation slides and related conference
More informationEdwards Lifesciences Corporation Unaudited Consolidated Statements of Operations
Unaudited Consolidated Statements of Operations Three Months Ended March 31, (in millions, except per share data) 2003 2002 Net sales $212.5 $162.3 Cost of goods sold 89.1 69.1 Gross profit 123.4 93.2
More informationFAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) June 30, September 30, 2018 2017 ASSETS: Current assets: Cash and cash equivalents $ 119,929 $ 105,618 Accounts receivable, net 182,419 168,586 Prepaid
More informationFAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) 2018 2017 ASSETS: Current assets: Cash and cash equivalents $ 90,023 $ 105,618 Accounts receivable, net 208,865 168,586 Prepaid expenses and other current
More informationFirst Quarter 2018 Earnings Call. May 10, 2018
First Quarter 2018 Earnings Call May 10, 2018 Forward-Looking Statements This presentation includes certain statements relating to future events and our intentions, beliefs, expectations, and predictions
More informationThird Quarter and Nine Months October 31, 2017
Third Quarter and Nine Months 2017 October 31, 2017 Welcome and Participants Vyomesh Joshi President & Chief Executive Officer John McMullen Executive Vice President & Chief Financial Officer Andy Johnson
More informationCORNING INCORPORATED AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF INCOME (Unaudited; in millions, except per share amounts)
CONSOLIDATED STATEMENTS OF INCOME (Unaudited; in millions, except per share amounts) Three months ended 2009 2008 Net sales $ 989 $ 1,617 Cost of sales 719 773 Gross margin 270 844 Operating expenses:
More informationSECOND QUARTER 2018 EARNINGS CONFERENCE CALL
SECOND QUARTER 2018 EARNINGS CONFERENCE CALL Forward Looking Statements & Non-GAAP Disclaimer The following information may contain forward-looking statements, including forward-looking statements within
More informationCFO COMMENTARY Q2 FY 2018
Q2 FY 2018 FINANCIAL INFORMATION AND CONFERENCE CALL Please see the accompanying earnings press release available at www.scansource.com in the Investor Relations section. The information included in this
More informationFOR IMMEDIATE RELEASE
Investor Contacts: Antonella Franzen +1-609-720-4665 afranzen@tyco.com Media Contact: Stephen Wasdick +1-609-806-2262 swasdick@tyco.com Ryan Edelman +1-609-720-4545 redelman@tyco.com FOR IMMEDIATE RELEASE
More informationFirst Quarter May 2, 2018
First Quarter 2018 May 2, 2018 Welcome and Participants Vyomesh Joshi President & Chief Executive Officer John McMullen Executive Vice President & Chief Financial Officer Andy Johnson Executive Vice President
More informationValeant Pharmaceuticals International, Inc. Fourth Quarter and Full Year 2015 Supplemental Information
Valeant Pharmaceuticals International, Inc. Fourth Quarter and Full Year Supplemental Information Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may
More informationNet sales $258.2 $234.6 $507.3 $469.6 Cost of goods sold Gross profit
Unaudited Consolidated Statements of Operations Three Months Ended Six Months Ended June 30, June 30, (in millions, except per share data) 2005 2004 2005 2004 Net sales $258.2 $234.6 $507.3 $469.6 Cost
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 489,353 $ 482,175 $ 964,148 $ 929,711 Cost of revenues 326,312 322,587 646,572 630,000 Gross profit
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 474,795 $ 447,536 Cost of revenues 320,260 307,413 Gross profit 154,535 140,123 Operating expenses
More informationECOLAB FOURTH QUARTER REPORTED DILUTED EPS $1.35 ADJUSTED DILUTED EPS $1.54, +12% 2019 ADJUSTED DILUTED EPS FORECAST $5.80 TO $6.
News Release Ecolab Inc. 1 Ecolab Place, St. Paul, Minnesota 55102 FOR IMMEDIATE RELEASE Michael J. Monahan (651) 250-2809 Andrew C. Hedberg (651) 250-2185 ECOLAB FOURTH QUARTER REPORTED DILUTED EPS $1.35
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 571,640 $ 563,691 Cost of revenues 388,535 378,713 Gross profit 183,105 184,978 Operating expenses
More informationSecond Quarter and Six Months August 2, 2017
Second Quarter and Six Months 2017 August 2, 2017 Welcome and Participants Vyomesh Joshi President & Chief Executive Officer John McMullen Executive Vice President & Chief Financial Officer Patrick Rogers
More informationECOLAB SECOND QUARTER REPORTED DILUTED EPS $1.20 ADJUSTED DILUTED EPS $1.27, +13% FULL YEAR 2018 ADJUSTED DILUTED EPS FORECAST $5.
News Release Ecolab Inc. 1 Ecolab Place, St. Paul, Minnesota 55102 FOR IMMEDIATE RELEASE Michael J. Monahan (651) 250-2809 Andrew C. Hedberg (651) 250-2185 ECOLAB SECOND QUARTER REPORTED DILUTED EPS $1.20
More informationSupplementary Materials First Quarter Fiscal 2018 Earnings Call
Supplementary Materials First Quarter Fiscal 2018 Earnings Call November 2, 2017 Safe Harbor This document contains forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 447,536 $ 571,640 Cost of revenues 307,413 388,535 Gross profit 140,123 183,105 Operating expenses
More informationEMERSON AND SUBSIDIARIES CONSOLIDATED OPERATING RESULTS (AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED)
CONSOLIDATED OPERATING RESULTS (AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED) Table 1 Quarter Ended March 31 Percent Change Net sales $3,579 $3,574 % Costs and expenses: Cost of sales 2,037 2,017 SG&A
More informationDigital River, Inc. Fourth Quarter Results (In thousands, except share data) Subject to reclassification
(In thousands, except share data) Consolidated Balance Sheets (Unaudited) 2012 2011 Assets Current assets Cash and cash equivalents $ 542,851 $ 497,193 Short-term investments 162,794 223,349 Accounts receivable,
More informationAnalog Devices, Fourth Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts) Nov.
Analog Devices, Fourth Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts) Revenue $ 814,247 $ 727,752 $ 678,133 $ 2,864,773 $ 2,633,689 Year-to-year
More informationSecond Quarter Review. 25 / April / 2014
Second Quarter Review 25 / April / 2014 Forward-Looking Statements / Safe Harbor This presentation contains a number of forward-looking statements. In many cases forward-looking statements are identified
More informationJuly 24, Q Supplemental Information
July 24, 2018 Q2 2018 Supplemental Information Non-GAAP Disclaimer The financial results disclosed in this presentation include certain measures calculated and presented in accordance with GAAP. In addition
More informationECOLAB FOURTH QUARTER 2018
4Q 2018 Overview Sales: ECOLAB FOURTH QUARTER 2018 Reported sales +3%; fixed currency sales were +6%, with acquisition adjusted fixed currency sales +6%. Strong momentum continues as new business growth,
More informationORACLE CORPORATION. Q4 FISCAL 2013 FINANCIAL RESULTS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ($ in millions, except per share data)
Q4 FISCAL 2013 FINANCIAL RESULTS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ( in millions, except per share data) REVENUES Software Revenues Hardware systems support Hardware Systems Revenues Services
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 504,063 $ 615,555 $ 1,654,843 $ 1,791,647 Cost of revenues 332,266 438,559 1,103,196 1,237,722 Gross
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 523,335 $ 642,477 $ 2,178,178 $ 2,434,124 Cost of revenues 359,835 449,944 1,463,031 1,687,666 Gross
More informationForward-looking Statement Disclosure
Third Quarter 2017 Earnings Call Presentation Valmont Industries. Inc. 2017 Investor Day Forward-looking Statement Disclosure These slides contain (and the accompanying oral discussion will contain) forwardlooking
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 470,103 $ 489,353 $ 918,350 $ 964,148 Cost of revenues 351,532 326,312 661,580 646,572 Gross profit
More informationDigital River, Inc. First Quarter Results (In thousands, except share data) Subject to reclassification
(In thousands, except share data) Consolidated Balance Sheets (Unaudited) December 31, Assets Current assets Cash and cash equivalents $ 500,742 $ 542,851 Short-term investments 144,615 162,794 Accounts
More informationCIRCOR Reports Fourth-Quarter and Year-End 2018 Financial Results
CIRCOR Reports Fourth-Quarter and Year-End 2018 Financial Results February 27, 2019 BURLINGTON, Mass.--(BUSINESS WIRE)--Feb. 26, 2019-- CIRCOR International, Inc. (NYSE: CIR), a leading provider of flow
More informationForward-looking Statement Disclosure
Fourth Quarter 2017 Earnings Call Presentation Valmont Industries. Inc. 2017 Investor Day Forward-looking Statement Disclosure These slides contain (and the accompanying oral discussion will contain) forwardlooking
More informationFOR IMMEDIATE RELEASE CONTACTS: Nina Devlin (Media) Kris King (Investors)
Filed by Mylan N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rules 14a 6 and 14d 2(b) of the Securities Exchange Act of 1934 Subject Company: Perrigo Company plc
More informationNon-GAAP Information 5/3/2018
5/3/2018 Use of Non-GAAP Financial Information: The Company believes that non-gaap performance measures, which management uses in evaluating the Company's business, may provide users of the Company's financial
More informationAlphabet Announces Third Quarter 2018 Results
Alphabet Announces Third Quarter 2018 Results MOUNTAIN VIEW, Calif. October 25, 2018 Alphabet Inc. (NASDAQ: GOOG, GOOGL) today announced financial results for the quarter ended. "Our business continues
More informationAlphabet Inc. CONSOLIDATED BALANCE SHEETS (In millions, except share amounts which are reflected in thousands and par value)
Assets Current assets: Alphabet Inc. CONSOLIDATED BALANCE SHEETS (In millions, except share amounts which are reflected in thousands and par value) As of December 31, 2015 As of December 31, 2016 (unaudited)
More informationQ Financial Supplement
Reconcilation of GAAP and Non-GAAP Financial Measures Non-GAAP Net Income and Non-GAAP EPS (in thousands except per share data) 2014 2015 Three Months Ending June 30, Low Range Guidance (1) High Range
More informationDISCOVERY, INC. REPORTS FIRST QUARTER 2018 RESULTS
THIS EARNINGS RELEASE IS UPDATED AS OF 5/9/2018 FOR MINOR TYPOGRAPHICAL ERRORS IN THE SUPPLEMENTAL FINANCIAL TABLES STARTING ON PAGE 10 OF THE RELEASE. DISCOVERY, INC. REPORTS FIRST QUARTER 2018 RESULTS
More informationMylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
November 6, Mylan Reports Third Quarter Results and Updates Guidance HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results
More informationQ Financial Results
Q2 2018 Financial Results August 1, 2018 Copyright Fortinet Inc. All rights reserved. Safe Harbor Statement Information, statements and projections contained in these presentation slides and related conference
More informationSECOND QUARTER 2017 EARNINGS RELEASE July 20, 2017
SECOND QUARTER 2017 EARNINGS RELEASE July 20, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments
More informationAVERY DENNISON ANNOUNCES SECOND QUARTER 2018 RESULTS
For Immediate Release AVERY DENNISON ANNOUNCES SECOND QUARTER 2018 RESULTS 2Q18 Reported EPS of $1.07 Adjusted EPS (non-gaap) of $1.66 2Q18 Net sales increased 14.0% to $1.85 billion Sales change ex. currency
More informationMcKesson Corporation Fiscal 2018 Financial Performance Fiscal 2019 Annual Outlook. Financial Results and Company Highlights May 24, 2018
McKesson Corporation Fiscal 2018 Financial Performance Fiscal 2019 Annual Outlook Financial Results and Company Highlights Forward-Looking Statements Some of the information in this presentation is not
More informationAlphabet Announces Fourth Quarter and Fiscal Year 2018 Results
Alphabet Announces Fourth Quarter and Fiscal Year 2018 Results MOUNTAIN VIEW, Calif. February 4, 2019 Alphabet Inc. (NASDAQ: GOOG, GOOGL) today announced financial results for the quarter and fiscal year
More informationFirst Quarter 2016 Business Update
Focused. First Quarter 2016 Business Update Innovative. Investor Presentation April 27, 2016 Performance Driven. Disclaimer Statement Regarding Safe Harbor For Forward-Looking Statements This presentation
More informationCIRCOR Reports Fourth-Quarter and Year-End 2013 Financial Results
30 CORPORATE DRIVE, SUITE 200 BURLINGTON, MA 01803 781-270-1200 WWW.CIRCOR.COM Press Release CIRCOR Reports Fourth-Quarter and Year-End Financial Results Burlington, MA February 27, 2014 CIRCOR International,
More informationQ Financial Results
Q3 2018 Financial Results November 1, 2018 Copyright Fortinet Inc. All rights reserved. 1 Safe Harbor Statement Information, statements and projections contained in these presentation slides and related
More informationECOLAB THIRD QUARTER REPORTED DILUTED EPS $1.48 ADJUSTED DILUTED EPS $1.53, +11% 2018 ADJUSTED DILUTED EPS FORECAST REDUCED TO $5.
News Release Ecolab Inc. 1 Ecolab Place, St. Paul, Minnesota 55102 FOR IMMEDIATE RELEASE Michael J. Monahan (651) 250-2809 Andrew C. Hedberg (651) 250-2185 ECOLAB THIRD QUARTER REPORTED DILUTED EPS $1.48
More informationWalgreens Boots Alliance 3Q16 Consolidated Financial Results Earnings conference call. 6 July 2016
Walgreens Boots Alliance 3Q16 Consolidated Financial Results Earnings conference call 6 July 2016 Agenda Topic Introduction & safe harbor Opening remarks Financial review Questions & answers Speaker Gerald
More informationEarnings per share: Basic $0.57 $1.26 Diluted $0.56 $1.24. Weighted-average common shares outstanding: Basic Diluted
Unaudited Consolidated Statements of Operations Three Months Ended March 31, (in millions, except per share data) 2014 2013 Net sales $522.4 $496.7 Cost of sales 145.9 121.0 Gross profit 376.5 375.7 Selling,
More informationColfax Reports Third Quarter 2018 Results
Colfax Reports Third Quarter Results October 25, ANNAPOLIS JUNCTION, MD, Oct. 25, (GLOBE NEWSWIRE) -- Reported net income from continuing operations per diluted share of $0.29 versus $0.35 in the prior
More informationColfax Reports First Quarter 2018 Results
Colfax Reports First Quarter 2018 Results Achieved net income per diluted share of $0.22 from continuing operations, and adjusted net income per share of $0.48 versus $0.39 in the prior year Grew sales
More informationFINANCIAL NEWS SANMINA REPORTS FOURTH QUARTER AND FISCAL YEAR END RESULTS
FINANCIAL NEWS SANMINA REPORTS FOURTH QUARTER AND FISCAL YEAR END RESULTS San Jose, CA October 29, 2018. Sanmina Corporation ( Sanmina or the Company ) (NASDAQ: SANM), a leading integrated manufacturing
More informationDANAHER CORPORATION Second Quarter 2018 Earnings Release. July 19, 2018
DANAHER CORPORATION Second Quarter 2018 Earnings Release July 19, 2018 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding the
More informationIQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More information